Alphabet’s drug-design company has raised $7.7 billion across three announced rounds. The next milestone is not another financing. It is a first human trial.
Isomorphic Labs raised $5 billion in a Series C announced Nov. 17, giving Alphabet’s AI drug-design company more than twice…
Positive Phase 3 leukemia results, progress in Parkinson’s drug delivery and a $2.2 billion acquisition agreement put clinical differentiation back at the center of the healthcare investment case.
Biotechnology’s most persuasive sales pitch is not a larger addressable-market slide. It is evidence…
A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
A Funded Biotech With a Date Worth Watching
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) is approaching a consequential clinical milestone with something that makes the occasion considerably more interesting: enough financial breathing room to focus on the science. The company’s November…
Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue
October 8, 2026
Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall…
Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…
Modular Medical (MODD) has cleared a crucial regulatory hurdle that positions its Pivot insulin patch pump as a potential game-changer in the $7 billion diabetes technology market, with FDA 510(k) clearance paving the way for commercial shipments by the end of Q2…
A new Ebola outbreak in Congo is once again testing global health systems, but it is also spotlighting a small group of vaccine developers who have spent the quiet years preparing for noisy ones like this. As health agencies scramble on the…
The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors.
FDA’s New Cast at the Top
The Food…
Investors are quietly building a new playbook: keep riding the AI rocket, but pair it with old‑economy resilience and under‑the‑radar healthcare innovators that actually move the needle in patients’ lives.
When Tech Flies Too Close to the Sun
Wall Street’s love affair…
